ArticleJournal of immunology research2014
S-calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis.
Article in Journal of immunology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Biomarkers in psoriatic arthritis: A meta-analysis and systematic review.Frontiers in immunology · 2022Pooled it
- Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.Arthritis research & therapy · 2016Trial
- Clinical and sonographic enthesitis in psoriatic arthritis patients and its relation to serum calprotectin level.Clinical rheumatology · 2026Article
- Evaluation of Serum Calprotectin Levels and Their Relationship with Disease Activity in Psoriatic Arthritis and Axial Spondyloarthritis.Medicina (Kaunas, Lithuania) · 2026Article
- Undulanoids A-D: Unexpected sesterterpenoids as potent S100A8/A9 complex inhibitors for psoriasis treatment.Acta pharmaceutica Sinica. B · 2025Article
- Article
- Characteristics and multi-omics analysis of spontaneous spondyloarthritis in non-human primates: Case report.Heliyon · 2025Article
- Effects of bile salt-stimulated lipase on blood cells and associations with disease activity in human inflammatory joint disorders.PloS one · 2023Article
- Is canine calprotectin in serum stabile after storage at low temperature?BMC veterinary research · 2022Article
- Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis.Biomedicines · 2022Review
- Serum Calprotectin Level Is Independently Associated With Carotid Plaque Presence in Patients With Psoriatic Arthritis.Frontiers in medicine · 2022Article
- Characterization of serum biomarkers and antibody responses againstFrontiers in cellular and infection microbiology · 2022Article
- From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis.Frontiers in immunology · 2022Review
- Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis.Arthritis research & therapy · 2020Article
- A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations.Arthritis research & therapy · 2020Article
- The Impact of Psoriasis and Metabolic Syndrome on the Systemic Inflammation and Oxidative Damage to Nucleic Acids.Journal of immunology research · 2020Article
- Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometry.Clinical proteomics · 2019Article
- Observational
- Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.Arthritis research & therapy · 2018Article
- [Novel molecular mechanisms in the pathophysiology of psoriatic arthritis].Zeitschrift fur Rheumatologie · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyse levels of S100A8/S100A9 (calprotectin) and selected cytokines, in blood, in patients with psoriatic arthritis (PsA).
methodsSixty-five patients with PsA were examined for clinical manifestations and laboratory measurements of S-calprotectin, ESR, hs-CRP, and selected cytokines. Thirty-two patients had mono-/oligoarthritis and 33 had polyarthritis. S-calprotectin, hs-CRP, and cytokines were measured using ELISA, immunoturbidimetry, and multiplex technology (Bio-Plex). Patients with PsA were compared with 31 healthy controls.
resultsS-calprotectin and hs-CRP levels were significantly higher in patients with PsA compared with controls (P<0.001 and P<0.001, resp.). Patients suffering a polyarthritic disease pattern presented with significantly higher levels of S-calprotectin compared with controls and patients with mono-/oligoarthritis (P<0.001 and P=0.017, resp.). The levels of S-calprotectin correlated with hs-CRP (P<0.001; rs=0.441), swollen joint count (P=0.002, rs=0.397), and CXCL10 (P=0.046, rs=0.678) but not with any of the other cytokines evaluated. In multiple logistic regression analysis, S-calprotectin was the only variable significantly associated with psoriatic arthritis (P=0.002, OR=1.006, 95% CI=1.002-1.010).
conclusionS-calprotectin and hs-CRP levels were significantly higher in patients with PsA. A polyarthritic disease pattern showed higher levels of S-calprotectin than mono-/oligoarthritis. S-calprotectin is considered a potential marker of disease activity in patients with PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.